drugset
drugset / Trial / NCT01674010

Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder

NCT01674010 ↗

Phase 2 Terminated 309 enrolled OPKO Health, Inc. Elan Pharmaceuticals · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary purpose of this study is to determine whether ELND005 is effective in the maintenance treatment of bipolar 1 disorder when added to other therapies.

Timeline

Start
2012-08
Primary completion
2014-06
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Subject SCYLLITOL Small molecule 500 mg Oral
Background Lamotrigine Small molecule — —
Background Valproic Acid Small molecule — —

Indications

bipolar I disorder